“r.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
According to the Middle East News Agency on 29 June, Favipiravir, the popular drug used to treat COVID-19, has shown the correct effects in clinical trials.AP, Fox and Deutsche Presse-Agentur also reported on Favipiravir’s role in a successful fight against the virus in China.
This multimedia press release. See the full edition here: https://www.businesswire.com/news/home/20200811005597/fr/
“Artillery Factory” in COVID-19 Combat in China – Zhejiang Hisun Pharmaceutical Headquarters in Zhejiang Province, China (Photo: Business Wire)
Favipiravir was originally developed through Toyama Chemical Co., Ltd.In 2016, Favipiravir’s patent was granted exclusively to Zhejiang Hisun Pharmaceutical Co., Ltd.(Hisun), who cooperated with CMAM to expand Favipiravir tablets.Chinese market in February 2020.Since the COVID-19 outbreak, favipiravir has been highly recommended by chinese and Japanese governments and has been used in clinical trials to treat COVID-19 since February.It has now been included in the diagnostic and treatment rules.Saudi Arabia, the United Arab Emirates and many other countries, and has been approved for indications of the disease in Russia and India.Stanford Medicine in the United States (https://www.clinicaltrialsarena.com/news/stanford-favipiravir- covid19-trial /) and the Italian Medicines Agency (AIFA) (https://europost.eu/en/a/view/ italy-starts-testing-antiviral-drug-avigan-against-covid-19-27664) also approved efficacy tests of Favipira vir on the new coronavirus.
Ongoing global multicenter clinical trials of favipiravir in the COVID-19 remedy have shown remarkable efficacy and safety. Hisun Favipiravir results compared to other drugs used in the virus remedy at Third People’s Hospital in Shenzhen showed that those taking Favipiravir tested negative for viral nucleic acid in a shorter period of time (four days), compared to the control organization (11 days); chest image enhancement rate greater than 91.43% compared to 62.22%, as well as a higher safety point.Inspiring effects were also observed in the early favipiravir clinical trials in Russia and Bangladesh: 60% of Russian patients (40 in total) and four8% (five0 in total) of Bangladeshi patients became negative after four to five days, all with no apparent side effects or side effects.
Hisun’s high-quality favipiravir, with a good enough supply, has passed through all channels in China.Following closely the global fight against COVID-19, Hisun has sent favipiravir to more than 20 countries since March.long-term partnerships with seven Middle Eastern countries to continue their fight against the disease.
Website: http://www.hisunpharm.com/en/favipiravir.php
See the edition in businesswire.com: https://www.businesswire.com/news/home/20200811005597/fr/
contacts
Ms. Li Huimin Email: [email protected]